Neuroimaging and therapeutics in movement disorders

被引：33

作者：

Eckert T. ^{[1
,2
]}

Eidelberg D. ^{[2
,3
,4
]}

机构：

[1] Dept. of Neurology II and Psychiatry, University of Magdeburg

[2] Center for Neurosciences, Institute for Medical Research, N. Shore-Long Isl. Jewish Hlth. S., Manhasset

[3] Department of Neurology, New York Univ. School of Medicine, New York

[4] Center for Neurosciences, Institute for Medical Research, N. Shore-Long Isl. Jewish Hlth. S., Manhasset, NY 11030

来源：

NeuroRX | 2005年 / 2卷 / 2期

关键词：

Dystonia; Huntington's disease; Magnetic resonance imaging (MRI); Movement disorders; Parkinson's disease; Positron emission tomography (PET); Tourette's syndrome;

D O I：

10.1602/neurorx.2.2.361

中图分类号：

学科分类号：

摘要：

In this review, we discuss the role of neuroimaging in assessing treatment options for movement disorders, particularly Parkinson's disease (PD). Imaging methods to assess dopaminergic function have recently been applied in trials of potential neuroprotective agents. Other imaging methods using regional metabolism and/or cerebral perfusion have been recently introduced to quantify the modulation of network activity as an objective marker of the treatment response. Both imaging strategies have provided novel insights into the mechanisms underlying a variety of pharmacological and stereotaxic surgical treatment strategies for PD and other movement disorders.

引用

页码：361 / 371

页数：10

共 124 条

[1]

Brooks D.J., Positron emission tomography and single-photon emission computed tomography in central nervous system drug development, NeuroRx, 2, pp. 226-236, (2005)

[2]

Ravina B., Eidelberg D., Ahlskog J.E., Albin R., Brooks D.J., Carbon M., Et al., The role of radiotracer imaging in Parkinson's disease, Neurology, 64, pp. 208-215, (2005)

[3]

Eidelberg D., Moeller J.R., Dhawan V., Spetsieris P., Takikawa S., Ishikawa T., Et al., The metabolic topography of parkinsonism, J Cereb Blood Flow Metab, 14, pp. 783-801, (1994)

[4]

Feigin A., Antonini A., Fukuda M., De Notaris R., Benti R., Pezzoli G., Et al., Tc-99m ethylene cysteinate dimer SPECT in the differential diagnosis of parkinsonism, Mov Disord, 17, pp. 1265-1270, (2002)

[5]

Eckert T., Eidelberg D., The role of functional neuroimaging in the differential diagnosis of idiopathic Parkinson's disease and multiple system atrophy, Clin Auton Res, 14, pp. 84-91, (2004)

[6]

Brooks D.J., Imaging end points for monitoring neuroprotection in Parkinson's disease, Ann Neurol, 53, (2003)

[7]

Marek K., Jennings D., Seibyl J., Dopamine agonists and Parkinson's disease progression: What can we learn from neuroimaging studies, Ann Neurol, 53, (2003)

[8]

Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression, JAMA, 287, pp. 1653-1661, (2002)

[9]

Fahn S., Oakes D., Shoulson I., Kieburtz K., Rudolph A., Lang A., Olanow C.W., Tanner C., Marek K., Levodopa and the progression of Parkinson's disease, N Engl J Med, 351, pp. 2498-2508, (2004)

[10]

Whone A.L., Watts R.L., Stoessl A.J., Davis M., Reske S., Nahmias C., Et al., Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study, Ann Neurol, 54, pp. 93-101, (2003)

← 1 2 3 4 5 6 7 8 9 10 →